"Vytorin has been a top-selling cholesterol drug for several years, generating billions of dollars in revenue for Merck and Schering-Plough. Even though the drug was being prescribed to millions of people, nobody really knew if it worked to remove plaque from arteries (which sort of makes you wonder why it was approved in the first place, right?), so Merck launched a clinical trial called ENHANCE to study the effectiveness of the drug.
The ENHANCE study was completed in April, 2006, and the results were turned over to Merck. As it turns out, Merck didn't like the results of the trial, so instead of....."click here to read the rest at News Target
